AMAM News and Press, Ambrx Biopharma Inc. American Depositary Shares (each representing seven) From 03/07/23

2023-03-07 12:39:41 ET Gainers: ThredUp ( TDUP ) +73% . WW International ( WW ) +49% . Unicycive ( UNCY ) +39% . Protagonist Therapeutics ( PTGX ) +32% . Bionomics ( BNOX ) +28% . Novo Integrated Sciences ( NVOS ) +25% ...

2023-03-07 11:28:43 ET Gainers: Unicycive ( UNCY ) +52% . Bionomics ( BNOX ) +49% . Novo Integrated Sciences ( NVOS ) +37% . Protagonist Therapeutics ( PTGX ) +34% . Allakos ( ALLK ) +22% . Losers: Cara ( CARA ) -28...

2023-03-07 08:27:38 ET Cara Therapeutics CARA -28% on Q4 results. Appreciate Holdings ( SFR ) -16% . Tremor International TRMR -12% on Q4 results. THOR Industries THO -11% on Q2 results. Ambrx Biopharma ( AMAM ) -9% . Avalon ...

2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...

Company to Transfer Stock Exchange Listing from NYSE to Nasdaq Ticker symbol will remain “AMAM” Ambrx Biopharma Inc. (NYSE: AMAM ) (“Ambrx” or “the Company”) today announced that it will voluntarily transfer its stock exchange listin...

Summary Ambrx shares faced delisting from the Nasdaq after a difficult 2022 that saw shares trade >$0.5. The company IPOd in June 2021, issuing 7m ADR shares and raising $126m. Ambrx had high hopes that lead candidate ARX788 could secure accelerated approval in HER+ breast cancer...

Performance Shipping ( PSHG ) -43% . Novavax ( NVAX ) -28% on Q4 earnings release . Tupperware Brands TUP -25% after posting preliminary results . First Horizon ( FHN ) -23% as TD says it won't receive regulatory OK in time for May close . M...

An interim analysis for ACE-Breast-02, a Phase 3 breast cancer clinical trial conducted by Ambrx Biopharma's ( NYSE: AMAM ) partner NovoCodex Biopharmaceuticals has met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a gr...

Interim analysis of the ACE-Breast-02 study being conducted by Ambrx’s partner, NovoCodex Biopharmaceuticals, was completed by the Independent Data Monitoring Committee (IDMC) The pivotal Phase 3 ACE-Breast-02 study met its pre-specified interim primary efficacy endpoint with stati...

TEGNA TGNA -22% after FCC orders hearing for Standard General sale . Mount Rainier Acquisition RNER -15% on FY earnings release . Ready Capital RC -12% on Q4 earnings release . Atlas Lithium ( ATLX ) -11% . Movella ( MVLA ) -10% . Ambrx ...